LUND, Sweden, Sept. 16, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) announced today that
the United States Patent and Trademark Office (USPTO) has issued
U.S. Patent No. 10,774,150 which covers compositions of matter
directed to Alligator's bispecific drug candidate ATOR-1015. The
granted patent's earliest expiry year is 2036.
"ATOR-1015 constitutes a new concept, a tumor-localizing
bispecific CTLA-4 antibody. Our invention addresses one of the key
challenges within immuno-oncology, i.e. the narrow therapeutic
window of CTLA-4 drugs. This is now protected by a granted US
patent," commented Per Norlén, CEO at Alligator Bioscience.
ATOR-1015 is developed for the treatment of metastatic cancer.
Promising safety data from the ongoing ATOR-1015 Phase I clinical
study was presented at ASCO in June
2020. The Phase I dose escalation study is planned to be
completed during the fourth quarter 2020 and the subsequent Phase
Ib efficacy study in malignant melanoma is due to start in
2021.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact person set out above, at 08:30 a.m. CEST
on September 16, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes five lead clinical and preclinical
drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527
(co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical
development by Shanghai Henlius Biotech Inc.). Alligator's shares
are listed on Nasdaq Stockholm (ATORX). The Company is
headquartered in Lund, Sweden. For
more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-receives-patent-approval-for-the-drug-candidate-ator-1015,c3194695
The following files are available for download:
https://mb.cision.com/Main/12681/3194695/1306686.pdf
|
Alligator Bioscience
receives patent approval for the drug candidate
ATOR-1015
|